Record overview
Status and phase
Status: NOT_YET_RECRUITING
Phase: PHASE2
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Condition: Potentially Resectable ALK Positive Non-Small Cell Lung Cancer
NCT06282536
Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: stale_update_signal | primary_completion_date_past_signal | long_recruitment_duration_signal
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.